Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04275999 · ClinicalTrials.gov registry record · Phase 2
Rosacea and Ivermectin
A Phase 2 study of Rosacea, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04275999: Completed Phase 2 study of Rosacea, sponsored by Wake Forest University Health Sciences.
NCT04275999 is a Phase 2 study of Rosacea that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 30 participants, below the 242-participant average among 23 other Rosacea trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04275999, a Phase 2 study of Rosacea, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary hypothesis is that weekly digital interactions and routine measurement of TEWL rates and SC hydration levels will promote patient adherence to maintenance ivermectin therapy and prevent disease relapse. The project will consist of a trial in which thirty subjects with rosacea receive ivermectin therapy and are randomized to receive either no intervention, a weekly digital survey to assess patient's attitudes towards ivermectin therapy, or a portal hydration measurement device that measures TEWL rates and SC hydration levels. The study team will measure adherence objectively in all groups with electronic monitors attached to the containers of the ivermectin, which all subjects will be told to use daily for maintenance therapy. Additionally, the hydration measurement device can transmit data to an Internet server via a smartphone using Bluetooth technology, thereby allowing providers to monitor a patient's TEWL rate and SC levels.
Primary Outcome
Electronic monitoring of the ivermectin
Conditions Studied
Interventions
- DRUG ivermectin
- BEHAVIORAL digital interaction
- DEVICE GPSkin
Study Locations (1)
North Carolina
- Wake Forest Health Sciences Dermatology - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-04-16 |
| Est. Completion | 2025-01-17 |
| Phase | Phase 2 |
What the finished NCT04275999 record still lists
NCT04275999 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 242-participant average among 23 other Rosacea trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 3 interventions - of which ivermectin is the first listed.
NCT04275999 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04275999 about?
NCT04275999 is a clinical study titled "Rosacea and Ivermectin". The primary hypothesis is that weekly digital interactions and routine measurement of TEWL rates and SC hydration levels will promote patient adherence to maintenance ivermectin therapy and prevent disease relapse. The project will consist of a trial in which thirty subjects with rosacea receive ive...
What is the current status of trial NCT04275999?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-04-16. Estimated completion is 2025-01-17.
What conditions does trial NCT04275999 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT04275999?
The interventions under investigation include: ivermectin (DRUG), digital interaction (BEHAVIORAL), GPSkin (DEVICE).
Who is sponsoring clinical trial NCT04275999?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04275999 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04275999's enrollment target sits among peer trials
30 20th of 23 higher than 4 of 23 other Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
-
AGN-199201 for the Treatment of Erythema With Rosacea
COMPLETED · Phase 2
-
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 2
-
A Study of DER 45-EV Gel to Treat Rosacea
COMPLETED · Phase 2
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI